{"id":4042,"date":"2025-03-31T18:11:56","date_gmt":"2025-03-31T18:11:56","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/gliclazide-txt\/"},"modified":"2025-03-31T18:11:56","modified_gmt":"2025-03-31T18:11:56","slug":"gliclazide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/gliclazide-txt\/","title":{"rendered":"Gliclazide.txt"},"content":{"rendered":"<h1>  Gliclazide   <\/h1>\n<p><H3>  CLINICAL USE <\/H3><br \/>\nNon-insulin dependent diabetes mellitus<H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>Initially: 40\u201380 mg daily, with breakfast, adjusted according to response up to 160 mg as a single dose; higher doses should be divided; maximum 320 mg daily<H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :323.4<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Approx 95<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : &lt;5<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :0.24<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :10\u201312 (MR: 12\u201320)\/Prolonged<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4><LI> 20 to 50  &amp;nbsp &amp;nbsp : Initially 20\u201340 mg daily. Use with caution and monitor<LI> 10 to 20  &amp;nbsp &amp;nbsp : Initially 20\u201340 mg daily. Use with caution and monitor<LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Initially 20\u201340 mg daily. Use with caution and monitor closely<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely to be dialysed. Dose as in GFR &lt;10 mL\/min<\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Unlikely to be dialysed. Dose as in GFR &lt;10 mL\/min <LI>HDF\/high flux  &amp;nbsp :Unlikely to be dialysed. Dose as in GFR &lt;10 mL\/min<LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Unlikely to be dialysed. Dose as in GFR 10 to 20   mL\/min <H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugs\n<li>Analgesics: effects enhanced by NSAIDs\n<li>Antibacterials: effects enhanced by  chloramphenicol, sulphonamides, and trimethoprim; effect reduced by rifamycins\n<li>Anticoagulants: effect possibly enhanced  by coumarins; also possibly changes to INR\n<li>  Antifungals: concentration increased by  fluconazole and miconazole and possibly voriconazole \u2013 avoid with miconazoleSulfinpyrazone: enhanced effect of  sulphonylureas<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>Oral <H4>  Rate of Administration  <\/H4>\u2013<H4>Comments<\/H4>\u2013<H4>  OTHER INFORMATION  <\/H4>Care should be exercised in patients with  hepatic and\/or renal impairment, and a small starting dose should be used with careful patient monitoringCompany contraindicates prescribing of  Diamicron in severe renal impairment, which they define as creatinine clearance below 40 mL\/min.<br \/>\n","protected":false},"excerpt":{"rendered":"<p>Gliclazide CLINICAL USE Non-insulin dependent diabetes mellitus DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4042","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4042"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4042\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}